Clinical Trials Logo

Reperfusion Injury clinical trials

View clinical trials related to Reperfusion Injury.

Filter by:

NCT ID: NCT00457405 Completed - Atherosclerosis Clinical Trials

Does a Seven Day Treatment With Dipyridamole Induce Protection Against Ischemia-Reperfusion Injury?

Start date: June 2007
Phase: Phase 4
Study type: Interventional

This study is performed to determine whether a seven day treatment with dipyridamole (slow release, 200mg twice daily) can induce a protective effect against ischemia-reperfusion injury, after ischemic exercise of the non-dominant forearm in healthy volunteers.

NCT ID: NCT00441714 Withdrawn - Clinical trials for Cardiovascular Disease

Effect of Ischemic Postconditioning on Targeting of Annexin A5 After Forearm Exercise

Start date: October 2007
Phase: N/A
Study type: Interventional

To adjust our forearm model for ischemia reperfusion injury, in order to used it for assessment of ischemia reperfusion damage in elderly and patients. To test the effect of ischemic postconditioning on ischemia reperfusion injury in healthy volunteers, using Annexin binding after repetitive handgripping.

NCT ID: NCT00441597 Completed - Clinical trials for Cardiovascular Disease

Does Atorvastatin Reduce Ischemia-Reperfusion Injury in Humans in-Vivo?

Start date: February 2007
Phase: Phase 4
Study type: Interventional

To study the impact of 3 day exposure to atorvastatin 80mg on Annexin A5 targeting after ischemic exercise in the non-dominant forearm.

NCT ID: NCT00430170 Completed - Clinical trials for Cardiovascular Disease

Does Caffeine Reduce Dipyridamole-Induced Protection Against Ischemia-Reperfusion Injury?

Start date: January 2007
Phase: Phase 4
Study type: Interventional

The purpose of this project is to explore the interaction between caffeine and dipyridamole on ischemia-reperfusion injury in the forearm.

NCT ID: NCT00405015 Completed - Clinical trials for Ischemia-Reperfusion Injury

The Effect of Rosiglitazone on Ischemia-reperfusion-injury Using Annexin A5 Scintigraphy.

Start date: April 2007
Phase: Phase 2
Study type: Interventional

Cardiovascular disease is the leading cause of death in diabetic patients due to both a high event rate and a worse outcome. A pharmacological intervention that reduces ischemia-reperfusion-injury would improve the outcome of diabetic patients after a cardiovascular event. In the present study, we will use annexinA5 scintigraphy to address the following hypothesis: Rosiglitazone reduces ischemia-reperfusion-injury in humans with insulin resistance.

NCT ID: NCT00402506 Completed - Myocardial Ischemia Clinical Trials

A Safety and Efficacy Study to Confirm the Cardioprotective Effects of MC-1 in Patients Undergoing High-Risk CABG

Start date: November 2006
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine the effect of MC-1 on the combined incidence of cardiovascular death and nonfatal myocardial infarction (MI) up to and including 30 days following coronary artery bypass graft (CABG) surgery compared with placebo.

NCT ID: NCT00385151 Completed - Clinical trials for Endothelial Dysfunction

To Compare the Ischemic Pre-conditioning and Post-conditioning on Reperfusion Injury in Humans.

Start date: May 2006
Phase: N/A
Study type: Observational

Reperfusion Injury occurs by the sudden blood flow to the injured and ischemic myocardium during restoration of blood flow either by Mechanical revascularization or thrombolysis. A phenomenon known as Pre-conditioning has been identified to limit the the extent and severity of reperfusion injury but it is very difficult to apply it in patient care setting as timing of acute cardiac or neurologic ischemic event is difficult to reliably predict. Postconditioning or ischemic postconditioning is well known to attenuate the reperfusion injury. There is enough data that shows the benefit of post conditioning in reducing the reperfusion injury in animals. However postconditioning in humans has not been investigated. We hypothesize that Post conditioning will attenuate the reperfusion injury and will be comparable to the effect of preconditioning in humans.

NCT ID: NCT00326976 Completed - Clinical trials for Myocardial Infarction

Efficacy of FX06 in the Prevention of Myocardial Reperfusion Injury

Start date: August 2006
Phase: Phase 2
Study type: Interventional

The purpose of the study is to evaluate whether FX06 is capable of limiting infarct size following balloon catheterization for acute myocardial infarction.

NCT ID: NCT00286312 Completed - Clinical trials for Myocardial Infarction

Myocardial Infarction Size Reduction With Atorvastatin

Start date: February 2006
Phase: Phase 4
Study type: Interventional

The purpose of this study is to determine if oral atorvastatin administered just before percutaneous coronary angioplasty for acute myocardial infarction improves early and late heart function as compared to placebo.

NCT ID: NCT00265239 Completed - Clinical trials for Myocardial Infarction

Pilot Study of Edaravone to Treat Acute Myocardial Infarction

Start date: April 2001
Phase: Phase 4
Study type: Interventional

Early reperfusion therapy has improved the clinical outcomes of patients with acute myocardial infarction (AMI), but these benefits are limited in some patients by reperfusion injuries. There is now increasing evidence that reactive oxygen species cause reperfusion injury. This study was designed to examine the effects of edaravone, a novel free radical scavenger, in patients with AMI.